{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:02:21Z","timestamp":1785150141853,"version":"3.55.0"},"reference-count":55,"publisher":"Academy of Managed Care Pharmacy","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.18553\/jmcp.2026.26066","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:54:45Z","timestamp":1783612485000},"page":"994-1006","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of renal and bone risk factors and nucleos(t)ide analogue treatment among patients with chronic hepatitis B in the United States"],"prefix":"10.18553","volume":"32","author":[{"given":"Alice E.","family":"Stead","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"Christoph","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda W.","family":"Singer","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Majethia","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Byrne","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woodie","family":"Zachry","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"r1","unstructured":"World Health Organization. Hepatitis B. 2024. Accessed April 11, 2025. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000651"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22980"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7201a1"},{"key":"r5","unstructured":"U.S. Department of Health and Human Services. Hepatitis B basic information. 2023. Accessed April 11, 2025. https:\/\/www.hhs.gov\/hepatitis\/learn-about-viral-hepatitis\/hepatitis-b-basics\/index.html"},{"key":"r6","unstructured":"U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion. Increase the proportion of people who know they have chronic hepatitis B \u2014 IID-13. 2020. Accessed December 5, 2025. https:\/\/odphp.health.gov\/healthypeople\/objectives-and-data\/browse-objectives\/infectious-disease\/increase-proportion-people-who-know-they-have-chronic-hepatitis-b-iid-13\/data-methodology"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000118"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1038\/s41424-018-0007-6"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30246"},{"key":"r10","unstructured":"Centers for Disease Control and Prevention. 2022 Viral hepatitis surveillance report. 2024. Accessed April 1, 2025. https:\/\/www.cdc.gov\/hepatitis-surveillance-2022\/about\/index.html"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09546-z"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-03991-x"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1419303"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206152"},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"r18","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2020"},{"issue":"8","key":"r19","first-page":"367","volume":"17","author":"Tsai E","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001195"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100847"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26301"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18278"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01146.x"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab241"},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14155"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.018"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001549"},{"key":"r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009756"},{"key":"r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.008"},{"key":"r32","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu471"},{"key":"r33","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-03027-4"},{"key":"r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.04.045"},{"key":"r35","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30421-2"},{"key":"r36","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12481"},{"key":"r37","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07212-w"},{"key":"r38","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000687"},{"key":"r39","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2087"},{"key":"r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijregi.2023.01.004"},{"key":"r41","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.SJG_447_18"},{"key":"r42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2022.11.012"},{"key":"r43","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30833"},{"key":"r44","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i23.2961"},{"key":"r45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.09.021"},{"key":"r46","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002468"},{"key":"r47","unstructured":"Kaiser Foundation Health Plan of the Northwest. Vemlidy (tenofovir alafenamide) \u2013 criteria-based consultation prescribing program. 2022. Accessed October 27, 2025. https:\/\/healthy.kaiserpermanente.org\/content\/dam\/kporg\/final\/documents\/formularies\/nw\/vemlidy-nw-en.pdf"},{"key":"r48","unstructured":"Ventegra, Inc. Medication policy: vemlidy (tenofovir alafenamide). 2023. Accessed October 27, 2025. https:\/\/www.ventegra.com\/medpolicies\/Medication%20Policy_Vemlidy.pdf"},{"key":"r49","unstructured":"Centene Corporation. Tenofovir alafenamide (vemlidy) clinical policy: CP.PMN.268. 2024. Accessed October 27, 2025. https:\/\/www.healthnet.com\/static\/general\/unprotected\/html\/national\/pa_guidelines\/1660.pdf"},{"key":"r50","unstructured":"UnitedHealthcare Pharmacy. Clinical pharmacy programs. Vemlidy\n                      \u00ae\n                      (tenofovir alafenamide). 2025. Accessed December 19, 2025. https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/prior-auth\/drugs-pharmacy\/commercial\/r-z\/PA-Med-Nec-Vemlidy.pdf"},{"key":"r51","doi-asserted-by":"publisher","DOI":"10.1186\/s12992-023-00922-z"},{"key":"r52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196713"},{"key":"r53","unstructured":"World Health Organization. Global health strategy on viral hepatitis 2016-2021. 2016. Accessed April 11, 2025. https:\/\/iris.who.int\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf?sequence=1"},{"key":"r54","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac385"},{"key":"r55","unstructured":"World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. 2024. Accessed April 29, 2025. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376353\/9789240090903-eng.pdf?sequence=1"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:41:13Z","timestamp":1785148873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.26066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.18553\/jmcp.2026.26066"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.26066","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}